Fallopian Tube Cancer – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Fallopian Tube Cancer – Pipeline Review, H1 2020’, provides an overview of the Fallopian Tube Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer

– The report reviews pipeline therapeutics for Fallopian Tube Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Fallopian Tube Cancer therapeutics and enlists all their major and minor projects

– The report assesses Fallopian Tube Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

ADC Therapeutics SA

Advenchen Laboratories LLC

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Amgen Inc

Anew Oncology Inc

Apexigen Inc

Apollomics Inc

Apotex Inc

Aravive Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

BioIntegrator Ltd

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celldex Therapeutics Inc

Celsion Corp

Celyad SA

Chipscreen Biosciences Ltd

Clovis Oncology Inc

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Cristal Therapeutics BV

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

Ellipses Pharma Ltd

ENB Therapeutics LLC

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

Gene Techno Science Co Ltd

Genentech Inc

Genmab AS

Gilead Sciences Inc

GlaxoSmithKline Plc

Gradalis Inc

I-Mab Biopharma Co Ltd

ImmunityBio Inc

ImmunoGen Inc

IMPACT Therapeutics Inc

IMV Inc

Incyte Corp

Innate Pharma SA

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kyowa Kirin Co Ltd

Leap Therapeutics Inc

Lokon Pharma AB

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MaxCyte Inc

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Moderna Inc

Mycenax Biotech Inc

Neon Therapeutics Inc

Northlake International LLC

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omnitura Therapeutics Inc

Oncoinvent AS

Oncolix Inc

Oncologie Inc

Oncolytics Biotech Inc

OncoQuest Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Plexxikon Inc

Prestige BioPharma Pte Ltd

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

R-Pharm US LLC

Regeneron Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

SELLAS Life Sciences Group Inc

Shenzen SiBiono GeneTech Co Ltd

Sotio AS

Sutro Biopharma Inc

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

Taiho Pharmaceutical Co Ltd

Tmunity Therapeutics Inc

Transgene SA

Vascular Biogenics Ltd

Verastem Inc

Vyriad Inc

Xcovery Holding Co LLC

Xencor Inc

Zymeworks Inc

Table of Contents

Table of Contents

Introduction

Fallopian Tube Cancer - Overview

Fallopian Tube Cancer - Therapeutics Development

Fallopian Tube Cancer - Therapeutics Assessment

Fallopian Tube Cancer - Companies Involved in Therapeutics Development

Fallopian Tube Cancer - Drug Profiles

Fallopian Tube Cancer - Dormant Projects

Fallopian Tube Cancer - Discontinued Products

Fallopian Tube Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Fallopian Tube Cancer – Pipeline by AB Science SA, H1 2020

Fallopian Tube Cancer – Pipeline by AbbVie Inc, H1 2020

Fallopian Tube Cancer – Pipeline by ADC Therapeutics SA, H1 2020

Fallopian Tube Cancer – Pipeline by Advenchen Laboratories LLC, H1 2020

Fallopian Tube Cancer – Pipeline by AiVita Biomedical Inc, H1 2020

Fallopian Tube Cancer – Pipeline by Aldeyra Therapeutics Inc, H1 2020

Fallopian Tube Cancer – Pipeline by Amgen Inc, H1 2020

Fallopian Tube Cancer – Pipeline by Anew Oncology Inc, H1 2020

Fallopian Tube Cancer – Pipeline by Apexigen Inc, H1 2020

List of Figures

List of Figures

Number of Products under Development for Fallopian Tube Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports